share_log

Anebulo Pharmaceuticals Analyst Ratings

Benzinga ·  Sep 21, 2023 11:48
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
09/21/2023 71.92% Maxim Group → $6 Initiates Coverage On → Buy
09/18/2023 71.92% HC Wainwright & Co. → $6 Initiates Coverage On → Buy
05/18/2023 129.23% Benchmark → $8 Reiterates Speculative Buy → Speculative Buy
02/14/2023 129.23% Benchmark $10 → $8 Maintains Speculative Buy
07/27/2022 71.92% Ladenburg Thalmann → $6 Initiates Coverage On → Buy
05/25/2021 329.8% Benchmark → $15 Initiates Coverage On → Buy

What is the target price for Anebulo Pharmaceuticals (ANEB)?

The latest price target for Anebulo Pharmaceuticals (NASDAQ: ANEB) was reported by Maxim Group on September 21, 2023. The analyst firm set a price target for $6.00 expecting ANEB to rise to within 12 months (a possible 71.92% upside). 4 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for Anebulo Pharmaceuticals (ANEB)?

The latest analyst rating for Anebulo Pharmaceuticals (NASDAQ: ANEB) was provided by Maxim Group, and Anebulo Pharmaceuticals initiated their buy rating.

When is the next analyst rating going to be posted or updated for Anebulo Pharmaceuticals (ANEB)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Anebulo Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Anebulo Pharmaceuticals was filed on September 21, 2023 so you should expect the next rating to be made available sometime around September 21, 2024.

Is the Analyst Rating Anebulo Pharmaceuticals (ANEB) correct?

While ratings are subjective and will change, the latest Anebulo Pharmaceuticals (ANEB) rating was a initiated with a price target of $0.00 to $6.00. The current price Anebulo Pharmaceuticals (ANEB) is trading at is $3.49, which is within the analyst's predicted range.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment